<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03782805</url>
  </required_header>
  <id_info>
    <org_study_id>222222</org_study_id>
    <nct_id>NCT03782805</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D Supplementation on Inflammatory Markers</brief_title>
  <official_title>Effect of Vitamin D Treatment on Some Inflammatory Markers in Non-obese Lebanese Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université d'Auvergne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université d'Auvergne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have shown that improving vitamin D status among the elderly may lead to an
      improvement in some inflammatory markers, especially with patients with type 2 diabetes. The
      aim of our trial is study the effect of vitamin D supplementation on inflammatory markers in
      patients having type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D was shown crucial for insulin secretion and glucose homeostasis. Furthermore, one
      of the markers of type 2 diabetes is low-grade inflammation, which can be the result of an
      elevated circulation of cytokines. High amounts of circulating inflammatory cytokines such as
      tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) contribute significantly to
      insulin resistance in muscle and adipose tissues. The aim of this randomized, controlled,
      double blind study is to examine the effect of vitamin D supplementation on some inflammatory
      markers in older Lebanese patients having type 2 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Actual">July 9, 2018</completion_date>
  <primary_completion_date type="Actual">June 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In this randomized, controlled, double blind study, participants were randomized (using the simple randomization method) to receive either a supplement of 10,000 IU of cholecalciferol (Euro-Pharm International, Canada) or a placebo tablet (containing microcrystalline cellulose: 66.3%, starch: 33.2%, magnesium stearate: 0.5%, per serving) to be taken 3 times a week for a period of six months</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Neither the investigator nor the subjects were aware of the group allocation; the pharmacist (in charge of the placebo tablets as well as the packing and coding of the supplements) was the only person to know to which group each participant belonged.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline fasting blood glucose (FBG) at 6 months</measure>
    <time_frame>baseline and after 6 months of intervention</time_frame>
    <description>FASTING BLOOD GLUCOSE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at 6 months</measure>
    <time_frame>baseline and after 6 months of intervention</time_frame>
    <description>Homeostatic Model Assessment of Insulin Resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline C-reactive protein (CRP) at 6 months</measure>
    <time_frame>baseline and after 6 months of intervention</time_frame>
    <description>C-reactive protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Interleukin-6 (IL-6) at 6 months</measure>
    <time_frame>baseline and after 6 months of intervention</time_frame>
    <description>Interleukin-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline TNF-alpha at 6 months</measure>
    <time_frame>baseline and after 6 months of intervention</time_frame>
    <description>TNF-alpha</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline weight at 6 months</measure>
    <time_frame>baseline and after 6 months of intervention</time_frame>
    <description>weight change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Body Mass Index (BMI) at 6 months</measure>
    <time_frame>baseline and after 6 months of intervention</time_frame>
    <description>Body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline waist circumference at 6 months</measure>
    <time_frame>baseline and after 6 months of intervention</time_frame>
    <description>Waist circumference change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Percentage of fat at 6 months</measure>
    <time_frame>baseline and after 6 months of intervention</time_frame>
    <description>Percentage of fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Parathyroid hormone (PTH) at 6 months</measure>
    <time_frame>baseline and after 6 months of intervention</time_frame>
    <description>Parathyroid hormone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group receiving a supplement of 10,000 IU of cholecalciferol (Euro-Pharm International, Canada) to be taken 3 times a week for a period of six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group receiving a placebo tablet (containing microcrystalline cellulose: 66.3%, starch: 33.2%, magnesium stearate: 0.5%, per serving) to be taken 3 times a week for a period of six months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol (Euro-Pharm International, Canada)</intervention_name>
    <description>The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects deficient in vitamin D

          -  Subjects having type 2 diabetes

          -  Non-obese subjects

        Exclusion Criteria:

          -  Subjects having hyperparathyroidism

          -  Subjects suffering from hepatic disease / kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia E Hajj, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Charles Hospital</name>
      <address>
        <city>Beirut</city>
        <zip>64</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <reference>
    <citation>Yu Y, Tian L, Xiao Y, Huang G, Zhang M. Effect of Vitamin D Supplementation on Some Inflammatory Biomarkers in Type 2 Diabetes Mellitus Subjects: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ann Nutr Metab. 2018;73(1):62-73. doi: 10.1159/000490358. Epub 2018 Jun 26.</citation>
    <PMID>29945132</PMID>
  </reference>
  <reference>
    <citation>Safarpour P, Vafa MR, Amiri F, Janani L, Noorbakhsh M, Rajabpour Nikoo E, Sadeghi H. A double blind randomized clinical trial to investigate the effect of vitamin D supplementation on metabolic and hepato-renal markers in type 2 diabetes and obesity. Med J Islam Repub Iran. 2018 Apr 28;32:34. doi: 10.14196/mjiri.32.34. eCollection 2018.</citation>
    <PMID>30159285</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 13, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>December 20, 2018</last_update_submitted>
  <last_update_submitted_qc>December 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitamin D, type 2 diabetes, inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The plan will be shared upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

